# Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)

> **NCT00496392** · PHASE3 · COMPLETED · sponsor: **Nycomed** · enrollment: 115 (estimated)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Nasal fentanyl

## Key facts

- **NCT ID:** NCT00496392
- **Lead sponsor:** Nycomed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-08
- **Final completion:** 2009-10
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496392, "Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00496392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*